These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 33672724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
    Urano T, Suzuki Y, Iwaki T, Sano H, Honkura N, Castellino FJ.
    Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
    [Abstract] [Full Text] [Related]

  • 3. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.
    Stringer HA, van Swieten P, Heijnen HF, Sixma JJ, Pannekoek H.
    Arterioscler Thromb; 1994 Sep; 14(9):1452-8. PubMed ID: 8068607
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H, Suzuki Y, Sano H, Suda T, Chida K, Dan T, Miyata T, Urano T.
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [Abstract] [Full Text] [Related]

  • 6. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
    Mutch NJ, Moore NR, Wang E, Booth NA.
    J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
    [Abstract] [Full Text] [Related]

  • 7. Microfluidic Modeling of Thrombolysis.
    Loyau S, Ho-Tin-Noé B, Bourrienne MC, Boulaftali Y, Jandrot-Perrus M.
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B, Livnat T, Budnik I, Tamarin I, Einav Y, Martinowitz U.
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [Abstract] [Full Text] [Related]

  • 14. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA, Huang TC, Keyt BA, Alevriadou BR.
    Ann Biomed Eng; 1998 Dec; 26(4):712-24. PubMed ID: 9662163
    [Abstract] [Full Text] [Related]

  • 15. High accumulation of plasminogen and tissue plasminogen activator at the flow surface of mural fibrin in the human arterial system.
    Sasajima T, Takano Y, Hiraishi Y, Goh K, Inaba M, Azuma N, Sasajima Y, Yamazaki K, Yamamoto H.
    J Vasc Surg; 2000 Aug; 32(2):374-82. PubMed ID: 10917998
    [Abstract] [Full Text] [Related]

  • 16. Redistribution of TPA Fluxes in the Presence of PAI-1 Regulates Spatial Thrombolysis.
    Shibeko AM, Chopard B, Hoekstra AG, Panteleev MA.
    Biophys J; 2020 Aug 04; 119(3):638-651. PubMed ID: 32653051
    [Abstract] [Full Text] [Related]

  • 17. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov 04; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.